Cytokine Therapy

Recombinant antibody directs interleukin-2 to tumor vessels

Published in Cancer Weekly, April 2nd, 2002

by Sonia Nichols, senior medical writer - Directing interleukin-2 to tumors has become easier with the concomitant use of a new antibody targeting extracellular matrix components.

Such therapy has proved fruitful for increasing antitumor response and diminishing tumor size in mice, according to B. Carnemolla and a team of investigators at the National Institute for Cancer Research in Genoa, Italy.

The new fusion protein therapy takes advantage of angiogenic properties of extracellular matrix (ECM) components to shrink tumors. "Angiogenesis-associated ECM components represent appealing targets for the selective delivery of therapeutic molecules to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-04-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry